

12/15/00



12-18-00

A/Box Sep

PTO/SB/05 (2/98)

Approved for use through 09/30/2000 OMB 0651-0032

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box →

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37C.F.R. §1.53(b))

Attorney Docket No.

PC10173BADJ

First Named Inventor or Application Identifier

DENG, RUITANG ET AL.

Title

COMPOSITIONS AND METHODS FOR PROTECTING ANIMALS FROM LENTIVIRUS-ASSOCIATED DISEASE SUCH AS HIV AND IMMUNODEFICIENCY VIRUS

Express Mail Label No.

EL162817622US

PC10173BADJ

09/30/00

12/15/00

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages 48]
(preferred arrangement set forth below)
- Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference in Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 11.3) [Total sheets 11]
4. ☒ Oath or Declaration [Total pages 3]
- a. ☐ Newly executed (original or copy)
- b. ☒ Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
- i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b).
5. ☒ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☒ Computer Readable Copy
- b. ☒ Paper Copy (identical to computer copy)
- c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☒ 37 C.F.R. §3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS) PTO-1449 ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ *Small Entity ☐ Statement filed in prior application, Status still proper and desired (PTO/SB/09-12)
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☒ Other: Priority Claim
09,378,810, filed August 23, 1999
60/097,645, filed August 24, 1998

*NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application No: 09/378,810

Prior application information: Examiner C. Drabik Group/Art Unit: 1635

18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or ☒ Correspondence address below

Name	Paul H. Ginsburg		
Address	Pfizer Inc		
Address	235 East 42nd Street, 20th Floor		
City	New York	State	New York
Country	United States Of America	Zip Code	10017-5755
Telephone	(212)573-2369	Fax	(212)573-1939

NAME (Print/type)	A. David Joraj	Registration No. (Attorney/Agent)	37,858
Signature		Date	October 31, 2000

USERS\DOCS\LA21952\LPADJ\3F8601\ DOC / 159702 / Utility Patent Appl for PC10173BADJ

EXPRESS MAIL NO. EL162817622US

FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1.
These are the fees effective October 1, 1997.

Small Entity payments must be supported by a small entity statement,
otherwise large entity fees must be paid. See Forms PTO/SB/09-12

See 37 C.F.R. §§ 1.27 and 1.28.

Total Amount of Payment (\$908.00

Complete if Known

Application Number	Not Yet Known
Filing Date	Concurrently Herewith
First Named Inventor	DENG, RUITANG, ET AL.
Examiner Name	C. DRABIK
Group/Art Unit	1635
Attorney Docket No.	PC10173BADJ

METHOD OF PAYMENT (check one)

1. ☒ The commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 16-1445

Deposit Account Name Pfizer Inc

☒ Charge Any Additional Fee Required Under 37 C.F.R. §§ 1.16 and 1.17. ☐ Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance.

2. ☐ Payment Enclosed:

☐ Check ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
101	710	201	355	Utility filing fee	710.00
106	320	206	160	Design filing fee	
107	480	207	245	Plant filing fee	
108	710	208	355	Reissue filing fee	
114	150	214	75	Provisional filing fee	
SUBTOTAL (1) (\$)					710.00

2. EXTRA CLAIM FEES

Total Claims	Extra Claims	Fee from below	Fee Paid
31	11	18	198.00
Independent Claims 3	0	80	0.00
Multiple Dependent	270		000.00

** or number previously paid, if greater; For Reissues, see below

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	80	202	40	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim, if not paid
109	80	209	40	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent
SUBTOTAL (2) (\$) 198.00				

3. ADDITIONAL FEES (continued)


Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late fee or oath	
127	50	227	25	Surcharge-late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	390	216	195	Extension for reply within second month	
117	890	217	445	Extension for reply within third month	
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,240	241	620	Petition to revive - unintentional	
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	600	244	300	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	240	126	240	Submission of Information Disclosure Statement	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))	
Other Fee (specify)					
Other Fee (specify)					

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

Type or Printed Name A. David Jorran

Signature 

Date 12-15-00

Complete (if Applicable)

Reg Number 37,858

Deposit Account User ID

EXPRESS MAIL EL162817622 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: *Deng, Ruitang, et al.* :

APPLICATION NO.: Not Yet Known : Examiner: C. Drabik

FILING DATE: Concurrently Herewith : Group Art Unit: 1635

TITLE: COMPOSITIONS AND METHODS FOR :
PROTECTING ANIMALS FROM
LENTIVIRUS-ASSOCIATED DISEASE
SUCH AS FELINE IMMUNODEFICIENCY
VIRUS

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

Sir:

CERTIFICATE UNDER 37 CFR 3.73(B)

Pfizer Inc. _____, a Corporation of the State of Delaware
(Name of Assignee) (Type of Assignee, e.g. corporation, partnership,
university, government agency, etc.)

certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application identified above.
The assignment was recorded in the Patent and Trademark Office at Reel
010099, Frame 0001, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application identified above, to
the current assignee as shown below:

1. From: _____ To: _____

The document was recorded in the Patent and Trademark Office at
Reel __, Frame __, or for which a copy thereof is attached.

2. From: _____ To: _____

The document was recorded in the Patent and Trademark Office at
Reel __, Frame __, or for which a copy thereof is attached.

3. From: _____ To: _____

The document was recorded in the Patent and Trademark Office at

Reel __, Frame __, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee.


I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Pfizer Inc.

December 15, 2000

Date

By:



A. David Joran
Patent Counsel
Reg. No. 37,858

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: *Deng, Ruitang, et al.* :

APPLICATION NO.: Not Yet Known : Examiner: C. Drabik

FILING DATE: Concurrently Herewith : Group Art Unit: 1635

TITLE: COMPOSITIONS AND METHODS FOR :
PROTECTING ANIMALS FROM
LENTIVIRUS-ASSOCIATED DISEASE
SUCH AS FELINE IMMUNODEFICIENCY
VIRUS

Commissioner for Patents
Box Sequence
Washington, D.C. 20231

Sir:

CERTIFICATE PURSUANT TO 37 C.F.R. §1.821(f)

Pursuant to 37 C.F.R. §1.821(f), I hereby certify that the information recorded in computer readable form submitted herewith in connection with the above-identified patent application is identical to the written sequence listing submitted herewith.

Respectfully submitted,



A. David Joran
Attorney for Applicants
Reg. No. 37,858

Date: December 15, 2000

Pfizer Inc.
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-3381